vidarabine has been researched along with Agammaglobulinemia in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoshino, A; Ikegame, K; Imai, K; Inoue, T; Kaida, K; Kanegane, H; Morio, T; Ogawa, H; Okada, M; Soma, T; Tamaki, H; Yamashita, M | 1 |
| Aurran-Schleinitz, T; Dartigeas, C; Feugier, P; Leprêtre, S; Letestu, R; Van Den Neste, E; Ysebaert, L | 1 |
| Ariga, T; Hershfield, MS; Imai, K; Kanegane, H; Miyawaki, T; Nomura, K; Santisteban, I; Taneichi, H; Wada, T; Yachie, A | 1 |
| Cabanillas, F; Liboy, I; Pavia, O; Rivera, E | 1 |
| Bunker, CB; Chapman, A; Dearden, CE; Dungarwalla, M; Field-Smith, A; Jameson, C; Matutes, E; Riley, U | 1 |
| Daguindau, N; Feugier, P; Perrot, A; Tomowiak, C | 1 |
| Alexandrescu, DT; Wiernik, PH | 1 |
| Anolik, J; Conners, C; Fisher, RI; Friedberg, JW; Kleiner, A; Rich, L; Walker, AR | 1 |
2 review(s) available for vidarabine and Agammaglobulinemia
| Article | Year |
|---|---|
Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
Topics: Agammaglobulinemia; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Neutropenia; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2012 |
[Chronic lymphoid leukemia and intravenous immunoglobulins].
Topics: Agammaglobulinemia; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multicenter Studies as Topic; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Time Factors; Treatment Outcome; Vidarabine | 2007 |
6 other study(ies) available for vidarabine and Agammaglobulinemia
| Article | Year |
|---|---|
Allogeneic stem cell transplantation for X-linked agammaglobulinemia using reduced intensity conditioning as a model of the reconstitution of humoral immunity.
Topics: Adult; Agammaglobulinemia; Antilymphocyte Serum; Cyclophosphamide; Genetic Diseases, X-Linked; Humans; Immunity, Humoral; Immunoglobulin A; Immunoglobulin M; Male; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2016 |
Successful bone marrow transplantation with reduced intensity conditioning in a patient with delayed-onset adenosine deaminase deficiency.
Topics: Adenosine Deaminase; Agammaglobulinemia; Bone Marrow Transplantation; Busulfan; Child, Preschool; Humans; Living Donors; Male; Severe Combined Immunodeficiency; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2013 |
High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication.
Topics: Adult; Agammaglobulinemia; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bacterial Infections; Causality; Female; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Rituximab; Vidarabine | 2006 |
Cutaneous Mycobacterium chelonae infection in chronic lymphocytic leukaemia.
Topics: Agammaglobulinemia; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Humans; Immunocompromised Host; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Opportunistic Infections; Skin Diseases, Bacterial; Vidarabine | 2007 |
Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia.
Topics: Agammaglobulinemia; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biomarkers; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prednisone; Prognosis; Retrospective Studies; Rituximab; Serum Globulins; Vidarabine | 2008 |
Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma.
Topics: Adult; Agammaglobulinemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; CD4 Lymphocyte Count; Cyclophosphamide; Female; Humans; Immunocompromised Host; Immunoglobulin Class Switching; Immunoglobulins, Intravenous; Immunologic Memory; Immunophenotyping; Lymphoma, Follicular; Rituximab; Sinusitis; Vidarabine | 2008 |